
The State Administration for Market Regulation (SAMR), China’s market regulator, announced on Thursday, January 27, its decision on an antitrust review that conditionally approves Advanced Micro Devices’ planned purchase of Xilinx.
The restrictive conditions will be effective for 6 years, after which the regulator will decide whether to remove them according to Advanced Micro Devices’ applications and share of the market, read a notice published by the SAMR on Thursday.
Among the conditions, the regulator demanded that no differential treatment should be provided to customers, in terms of price, delivery time, and after-sales service, among other transaction conditions.
Some speculated that the acquisition has or may have the effect of restricting or eliminating competition in the global and domestic integrated circuit markets. However, after the assessment, the SAMR stated that the commitment plan proposed by the company on January 13 on additional restrictive conditions can reduce the adverse impact of the acquisition.
Other concerns were based on the fact that it is difficult for new competitors to be visible in the market in the short term and consolidate an effective competition since the industry requires large amounts of money and time.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas